Oihane Ibarguengoitia-Barrena , Leyre Riancho-Zarrabeitia , Zulema Plaza , Íñigo Rúa-Figueroa , Karen Roberts , Víctor Martínez-Taboada , Raúl Menor-Almagro , Belén Serrano-Benavente , Paula Rubio-Muñoz , María Galindo-Izquierdo , Antonio Fernández-Nebro , M.E. Ruiz-Lucea , Jaime Calvo-Alén , Eva G. Tomero-Muriel , Esther Uriarte-Isacelaya , Angela Pecondon-Españo , Mercedes Freire , Javier García-Fernández , Lorena Expósito , Mónica Ibañez-Barceló , José M. Pego-Reigosa
{"title":"系统性红斑狼疮的血清学聚集及其临床和预后意义:一项纵向队列研究","authors":"Oihane Ibarguengoitia-Barrena , Leyre Riancho-Zarrabeitia , Zulema Plaza , Íñigo Rúa-Figueroa , Karen Roberts , Víctor Martínez-Taboada , Raúl Menor-Almagro , Belén Serrano-Benavente , Paula Rubio-Muñoz , María Galindo-Izquierdo , Antonio Fernández-Nebro , M.E. Ruiz-Lucea , Jaime Calvo-Alén , Eva G. Tomero-Muriel , Esther Uriarte-Isacelaya , Angela Pecondon-Españo , Mercedes Freire , Javier García-Fernández , Lorena Expósito , Mónica Ibañez-Barceló , José M. Pego-Reigosa","doi":"10.1016/j.semarthrit.2025.152819","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disorder characterized by multi-organ involvement and variable clinical manifestations. Recurrent clinical patterns suggest distinct phenotypes, where cluster analysis of autoantibodies could identify prognostic subtypes.</div></div><div><h3>Objectives</h3><div>To define and describe serological clusters and their clinical-epidemiological characteristics, as well as their association with comorbidities, disease activity measures, severity, and damage.</div></div><div><h3>Materials and methods</h3><div>Descriptive, observational, and multicenter study including SLE patients from the Spanish Registry RELESSER. Gower distance was used for cluster analysis.</div></div><div><h3>Results</h3><div>A total of 1,740 patients from the cross-sectional phase and 718 from the prospective phase with a four-year follow-up were included. Four serological clusters were identified. Cluster 1 (negative for extractable nuclear antigen [ENA]) was characterized by a lower frequency of vasculitis, leukopenia, and lymphopenia. Cluster 2 (positive antiphospholipid antibodies) more frequently presented haemolytic anaemia, thrombocytopenia, vasculitis and visual alterations and required greater use of immunoglobulins and oral anticoagulants. Cluster 3 (positive anti-SSA/Ro and anti-SSB/La) had a lower incidence of lupus nephritis. Cluster 4 (positive anti-Sm and anti-ribonucleoproteins) was characterized by higher rates of lupus nephritis, leukopenia, lymphopenia, hypocomplementemia, myositis and cutaneous manifestations and greater use of glucocorticoids and immunosuppressants. Patients in cluster 2 had higher baseline damage scores measured by the SLICC/ACR DI (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index), while patients in cluster 4 had higher severity scores measured by the Katz Index. These differences among clusters persisted over the four-year of follow-up.</div></div><div><h3>Conclusion</h3><div>In our SLE patient population, the serological profile is key not only for clinical stratification but also for prognostic value.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"Article 152819"},"PeriodicalIF":4.4000,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Serological clusters in systemic lupus erythematosus and its clinical and prognostic implications: A longitudinal cohort study\",\"authors\":\"Oihane Ibarguengoitia-Barrena , Leyre Riancho-Zarrabeitia , Zulema Plaza , Íñigo Rúa-Figueroa , Karen Roberts , Víctor Martínez-Taboada , Raúl Menor-Almagro , Belén Serrano-Benavente , Paula Rubio-Muñoz , María Galindo-Izquierdo , Antonio Fernández-Nebro , M.E. Ruiz-Lucea , Jaime Calvo-Alén , Eva G. Tomero-Muriel , Esther Uriarte-Isacelaya , Angela Pecondon-Españo , Mercedes Freire , Javier García-Fernández , Lorena Expósito , Mónica Ibañez-Barceló , José M. Pego-Reigosa\",\"doi\":\"10.1016/j.semarthrit.2025.152819\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disorder characterized by multi-organ involvement and variable clinical manifestations. Recurrent clinical patterns suggest distinct phenotypes, where cluster analysis of autoantibodies could identify prognostic subtypes.</div></div><div><h3>Objectives</h3><div>To define and describe serological clusters and their clinical-epidemiological characteristics, as well as their association with comorbidities, disease activity measures, severity, and damage.</div></div><div><h3>Materials and methods</h3><div>Descriptive, observational, and multicenter study including SLE patients from the Spanish Registry RELESSER. Gower distance was used for cluster analysis.</div></div><div><h3>Results</h3><div>A total of 1,740 patients from the cross-sectional phase and 718 from the prospective phase with a four-year follow-up were included. Four serological clusters were identified. Cluster 1 (negative for extractable nuclear antigen [ENA]) was characterized by a lower frequency of vasculitis, leukopenia, and lymphopenia. Cluster 2 (positive antiphospholipid antibodies) more frequently presented haemolytic anaemia, thrombocytopenia, vasculitis and visual alterations and required greater use of immunoglobulins and oral anticoagulants. Cluster 3 (positive anti-SSA/Ro and anti-SSB/La) had a lower incidence of lupus nephritis. Cluster 4 (positive anti-Sm and anti-ribonucleoproteins) was characterized by higher rates of lupus nephritis, leukopenia, lymphopenia, hypocomplementemia, myositis and cutaneous manifestations and greater use of glucocorticoids and immunosuppressants. Patients in cluster 2 had higher baseline damage scores measured by the SLICC/ACR DI (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index), while patients in cluster 4 had higher severity scores measured by the Katz Index. These differences among clusters persisted over the four-year of follow-up.</div></div><div><h3>Conclusion</h3><div>In our SLE patient population, the serological profile is key not only for clinical stratification but also for prognostic value.</div></div>\",\"PeriodicalId\":21715,\"journal\":{\"name\":\"Seminars in arthritis and rheumatism\",\"volume\":\"74 \",\"pages\":\"Article 152819\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2025-08-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminars in arthritis and rheumatism\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0049017225001908\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in arthritis and rheumatism","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0049017225001908","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
Serological clusters in systemic lupus erythematosus and its clinical and prognostic implications: A longitudinal cohort study
Introduction
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disorder characterized by multi-organ involvement and variable clinical manifestations. Recurrent clinical patterns suggest distinct phenotypes, where cluster analysis of autoantibodies could identify prognostic subtypes.
Objectives
To define and describe serological clusters and their clinical-epidemiological characteristics, as well as their association with comorbidities, disease activity measures, severity, and damage.
Materials and methods
Descriptive, observational, and multicenter study including SLE patients from the Spanish Registry RELESSER. Gower distance was used for cluster analysis.
Results
A total of 1,740 patients from the cross-sectional phase and 718 from the prospective phase with a four-year follow-up were included. Four serological clusters were identified. Cluster 1 (negative for extractable nuclear antigen [ENA]) was characterized by a lower frequency of vasculitis, leukopenia, and lymphopenia. Cluster 2 (positive antiphospholipid antibodies) more frequently presented haemolytic anaemia, thrombocytopenia, vasculitis and visual alterations and required greater use of immunoglobulins and oral anticoagulants. Cluster 3 (positive anti-SSA/Ro and anti-SSB/La) had a lower incidence of lupus nephritis. Cluster 4 (positive anti-Sm and anti-ribonucleoproteins) was characterized by higher rates of lupus nephritis, leukopenia, lymphopenia, hypocomplementemia, myositis and cutaneous manifestations and greater use of glucocorticoids and immunosuppressants. Patients in cluster 2 had higher baseline damage scores measured by the SLICC/ACR DI (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index), while patients in cluster 4 had higher severity scores measured by the Katz Index. These differences among clusters persisted over the four-year of follow-up.
Conclusion
In our SLE patient population, the serological profile is key not only for clinical stratification but also for prognostic value.
期刊介绍:
Seminars in Arthritis and Rheumatism provides access to the highest-quality clinical, therapeutic and translational research about arthritis, rheumatology and musculoskeletal disorders that affect the joints and connective tissue. Each bimonthly issue includes articles giving you the latest diagnostic criteria, consensus statements, systematic reviews and meta-analyses as well as clinical and translational research studies. Read this journal for the latest groundbreaking research and to gain insights from scientists and clinicians on the management and treatment of musculoskeletal and autoimmune rheumatologic diseases. The journal is of interest to rheumatologists, orthopedic surgeons, internal medicine physicians, immunologists and specialists in bone and mineral metabolism.